226 related articles for article (PubMed ID: 9327137)
1. Method for radioiodination of proteins using N-succinimidyl 3-hydroxy-4-iodobenzoate.
Vaidyanathan G; Affleck DJ; Zalutsky MR
Bioconjug Chem; 1997; 8(5):724-9. PubMed ID: 9327137
[TBL] [Abstract][Full Text] [Related]
2. Radioiodination of proteins using N-succinimidyl 4-hydroxy-3-iodobenzoate.
Vaidyanathan G; Affleck DJ; Zalutsky MR
Bioconjug Chem; 1993; 4(1):78-84. PubMed ID: 8431515
[TBL] [Abstract][Full Text] [Related]
3. Preparation of N-succinimidyl 3-[*I]iodobenzoate: an agent for the indirect radioiodination of proteins.
Vaidyanathan G; Zalutsky MR
Nat Protoc; 2006; 1(2):707-13. PubMed ID: 17406300
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent.
Shankar S; Vaidyanathan G; Affleck DJ; Peixoto K; Bigner DD; Zalutsky MR
Nucl Med Biol; 2004 Oct; 31(7):909-19. PubMed ID: 15464393
[TBL] [Abstract][Full Text] [Related]
5. Radiohalogenation of a monoclonal antibody using an N-succinimidyl 3-(tri-n-butylstannyl)benzoate intermediate.
Zalutsky MR; Narula AS
Cancer Res; 1988 Mar; 48(6):1446-50. PubMed ID: 3345515
[TBL] [Abstract][Full Text] [Related]
6. Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer.
Wilbur DS; Hadley SW; Hylarides MD; Abrams PG; Beaumier PA; Morgan AC; Reno JM; Fritzberg AR
J Nucl Med; 1989 Feb; 30(2):216-26. PubMed ID: 2738650
[TBL] [Abstract][Full Text] [Related]
7. Assessment of radiochemical design of antibodies using an ester bond as the metabolizable linkage: evaluation of maleimidoethyl 3-(tri-n-butylstannyl)hippurate as a radioiodination reagent of antibodies for diagnostic and therapeutic applications.
Arano Y; Wakisaka K; Ohmono Y; Uezono T; Akizawa H; Nakayama M; Sakahara H; Tanaka C; Konishi J; Yokoyama A
Bioconjug Chem; 1996; 7(6):628-37. PubMed ID: 8950481
[TBL] [Abstract][Full Text] [Related]
8. Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate.
Zalutsky MR; Noska MA; Colapinto EV; Garg PK; Bigner DD
Cancer Res; 1989 Oct; 49(20):5543-9. PubMed ID: 2477144
[TBL] [Abstract][Full Text] [Related]
9. Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.
Shankar S; Vaidyanathan G; Kuan CT; Bigner DD; Zalutsky MR
Nucl Med Biol; 2006 Jan; 33(1):101-10. PubMed ID: 16459265
[TBL] [Abstract][Full Text] [Related]
10. Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
Reist CJ; Garg PK; Alston KL; Bigner DD; Zalutsky MR
Cancer Res; 1996 Nov; 56(21):4970-7. PubMed ID: 8895752
[TBL] [Abstract][Full Text] [Related]
11. Optimization of a convenient route to produce N-succinimidyl 4-radiodobenzoate for radioiodination of proteins.
Araujo EB; Santos JS; Colturato MT; Muramoto E; Silva CP
Appl Radiat Isot; 2003 Jun; 58(6):667-73. PubMed ID: 12798375
[TBL] [Abstract][Full Text] [Related]
12. Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination.
Wilbur DS; Chyan MK; Hamlin DK; Vessella RL; Wedge TJ; Hawthorne MF
Bioconjug Chem; 2007; 18(4):1226-40. PubMed ID: 17583925
[TBL] [Abstract][Full Text] [Related]
13. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
Foulon CF; Reist CJ; Bigner DD; Zalutsky MR
Cancer Res; 2000 Aug; 60(16):4453-60. PubMed ID: 10969792
[TBL] [Abstract][Full Text] [Related]
14. Enhanced binding and inertness to dehalogenation of alpha-melanotropic peptides labeled using N-succinimidyl 3-iodobenzoate.
Garg PK; Alston KL; Welsh PC; Zalutsky MR
Bioconjug Chem; 1996; 7(2):233-9. PubMed ID: 8983345
[TBL] [Abstract][Full Text] [Related]
15. Radioimmunotherapy of MCF7 breast cancer cell line with 131I-PR81 monoclonal antibody against MUC1: comparison of direct and indirect radioiodination methods.
Mohammadnejad J; Rasaee MJ; Babaei MH; Paknejad M; Hasan ZM; Salouti M; Gandomkar M; Sadri K
Hum Antibodies; 2010; 19(1):15-25. PubMed ID: 20555127
[TBL] [Abstract][Full Text] [Related]
16. N-succinimidyl 3-[(131)I]iodo-4-phosphonomethylbenzoate ([(131)I]SIPMB), a negatively charged substituent-bearing acylation agent for the radioiodination of peptides and mAbs.
Shankar S; Vaidyanathan G; Affleck D; Welsh PC; Zalutsky MR
Bioconjug Chem; 2003; 14(2):331-41. PubMed ID: 12643743
[TBL] [Abstract][Full Text] [Related]
17. Optimal quality (131)I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN.
Visser GW; Klok RP; Gebbinck JW; ter Linden T; van Dongen GA; Molthoff CF
J Nucl Med; 2001 Mar; 42(3):509-19. PubMed ID: 11337531
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of iodovinyl antibody conjugates: comparison with a p-iodobenzoyl conjugate and direct radioiodination.
Hadley SW; Wilbur DS
Bioconjug Chem; 1990; 1(2):154-61. PubMed ID: 2095212
[TBL] [Abstract][Full Text] [Related]
19. Labeling proteins using aryl iodide acylation agents: influence of meta vs para substitution on in vivo stability.
Garg PK; Slade SK; Harrison CL; Zalutsky MR
Int J Rad Appl Instrum B; 1989; 16(7):669-73. PubMed ID: 2613522
[TBL] [Abstract][Full Text] [Related]
20. 211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation.
Larsen RH; Murud KM; Akabani G; Hoff P; Bruland OS; Zalutsky MR
J Nucl Med; 1999 Jul; 40(7):1197-203. PubMed ID: 10405142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
